Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17331
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGleeson, Mary-
dc.contributor.authorHawkes, Eliza A-
dc.contributor.authorPeckitt, Clare-
dc.contributor.authorWotherspoon, Andrew-
dc.contributor.authorAttygalle, Ayoma-
dc.contributor.authorSharma, Bhupinder-
dc.contributor.authorDu, Yong-
dc.contributor.authorEthell, Mark-
dc.contributor.authorPotter, Mike-
dc.contributor.authorDearden, Claire-
dc.contributor.authorHorwich, Alan-
dc.contributor.authorChau, Ian-
dc.contributor.authorCunningham, David-
dc.date2016-12-08-
dc.date.accessioned2018-04-03T04:55:59Z-
dc.date.available2018-04-03T04:55:59Z-
dc.date.issued2017-08-
dc.identifier.citationLeukemia & lymphoma 2017; 58(8): 1805-1813-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/17331-
dc.description.abstractSurvival for transformed follicular lymphoma (tFL) has improved in the rituximab era and the need for upfront stem cell transplantation (SCT) is unclear. We evaluated the outcomes for all patients treated with first-line chemotherapy for histologically-proven tFL at our institution from 2003-2013 (n = 87). The majority of patients (89.7%) did not receive a SCT as part of first-line management. With a median follow-up of 7.8 years the 5-year overall survival (OS) for all patients was 61.7%. Patients treated with R-CHOP without upfront SCT (n = 55/87) had a 5-year OS of 64.3%. In a Cox regression analysis of the entire cohort (n = 87) International Prognostic Index (IPI) risk group and presence of B symptoms at transformation were independently associated with OS in multivariate analysis (MVA). Our analysis confirms the improved survival of tFL in the rituximab era even in the absence of upfront SCT consolidation.-
dc.language.isoeng-
dc.subjectFollicular lymphoma-
dc.subjecthigh-grade transformation-
dc.subjectrituximab era-
dc.subjectstem-cell transplantation-
dc.titleOutcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013.-
dc.typeJournal Article-
dc.identifier.journaltitleLeukemia & lymphoma-
dc.identifier.affiliationThe Royal Marsden Hospital, London and Surrey, United Kingdom-
dc.identifier.affiliationDepartment of Oncology and Clinical Haematology, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationEastern Health, Melbourne, Australia-
dc.identifier.doi10.1080/10428194.2016.1265114-
dc.identifier.pubmedid27931133-
dc.type.austinJournal Article-
local.name.researcherHawkes, Eliza A
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptClinical Haematology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

6
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.